Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.

Also called NCT01823185

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Imam Abdulrahman Bin Faisal University (from the registry)
Registry
  • NCT NCT01823185
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Saudi Arabia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01823185. Non-randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2016-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
Condition
Heart Disease
Condition
Vascular Disease
Condition
Angina Pectoris
Condition
Cardiovascular Disease
Condition
Ischemia
Condition
Infarction
Condition
Embolism
Condition
Thrombosis
Condition
Chest Pain
Intervention (Drug)
clopidogrel
Intervention (Drug)
Ticagrelor or prasugrel
Lead sponsor
Imam Abdulrahman Bin Faisal University (class: other)
Collaborator
King Fahad Armed Forces Hospital (class: other government)
Collaborator
Dammam Central Hospital (class: other)

Record details

Record id
cardio:ct-nct01823185
Content hash
6b70e21660de8bcc7b8b29dc265271a5b3092938b9ad78e389a7bfbdc167cf83